

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Curaleaf Holdings, Inc. (the "Issuer").

Trading Symbol: CURA

Number of Outstanding Listed Securities: 338,478,604

Date: April 4, 2019

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

General

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is the leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 43 dispensaries, 13 cultivation sites and 11 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as the CBD category through its Curaleaf Hemp brand.

Recent developments regarding the Issuer's business and operations

On March 13, 2019, Curaleaf announced its earnings call scheduled for March 20, 2019, on which date Curaleaf announced its Fourth Quarter 2018 Financial and Operational Results.

Please see the press releases dated March 13, 2019 and March 20, 2019, on the Issuer's website for more information.

On March 18, 2019, the Issuer announced the signature of a definitive agreement to acquire Acres Cannabis.

Please see the Issuer's press release dated March 18, 2019 on the Issuer's website for more information, the Issuer's Form 9 posted on March 26, 2019 and Section 7 of this report for further details.

On March 21, 2019, Curaleaf announced the opening of its 23rd Florida dispensary, featuring Miami's first medical marijuana drive-thru.

Please see the press release dated March 21, 2019 on the Issuer's website for more information.

On March 21, 2019, Curaleaf announced the opening of its dispensary in Gainesville, Florida.

Please see the press release dated March 21, 2019 on the Issuer's website for more information.

On March 28, 2019, Curaleaf and the Veterans Cannabis Project announced the launch of a national initiative to support Veterans' access to medical cannabis.

Please see the press releases dated March 28, 2019 on the Issuer's website for more information.

On March 29, 2019, the Issuer closed on its acquisition of Eureka Investment Partners, LLC. Please see the Issuer's press releases dated February 27, 2019 and April 1, 2019 on the Issuer's website for more information, the Issuer's Form 9 posted on March 28, 2019 and Section 7 of this report for further details.

Nil shares were repurchased in March in connection with the normal course issuer bid ("NCIB"), the details of which were reported in the Form 7 filed by the Issuer on January 8, 2019.

2. Provide a general overview and discussion of the activities of management.

Joseph F. Lusardi appeared on CNBC's news show "Closing Bell" on March 21, 2019 to discuss Curaleaf and the cannabis industry.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was

determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

ACRES CANNABIS

On March 18, 2019, the Issuer announced the signature of a definitive agreement to acquire Acres Cannabis (“Acres”).

With 269,000 sq. ft. of operating cultivation facilities and further expansion as needed on its 37 acres of land in Amargosa Valley, Nevada, Acres operates the state's largest cultivation facility, a state-of-the-art production and extraction lab and an immersive cannabis dispensary located in the city of Las Vegas, adjacent to the Strip, with a second dispensary under construction.

Acres also operates an award winning 19,000 sq. ft. dispensary in Las Vegas, NV. The cannabis experiential store is open 24 hours a day, 7 days a week, and hosts America's first marijuana farmers market every weekend. Steeped in the cannabis culture, the facilities offer a museum and open view processing kitchen where customers can view the processing of edibles and extracts. Acres also has a second dispensary in Ely, Nevada currently under construction and scheduled to open later this year.

The transaction, valued at US\$70 million, with US\$25 million to be paid in cash, US\$45 million to be paid in Curaleaf stock and additional consideration to be paid if certain financial targets are exceeded, is subject to customary closing conditions.

Please see the Issuer’s press release dated March 18, 2019 on the Issuer’s website for more information and the Issuer’s Form 9 for further details.

EUREKA INVESTMENT PARTNERS, LLC

On April 1, 2019, the Issuer announced the closing of its previously-announced acquisition of Eureka Investment Partners, LLC (“Eureka”).

Based in Monterey County, California, Eureka operates a cultivation facility in the Salinas Valley and is developing three dispensaries across the state. Eureka operates a 110,000 sq. ft. greenhouse facility in Salinas, California. During the fourth quarter of 2018, Eureka harvested over 2,500 pounds of flower and distributed pre-rolls and dry flower under the brand Monterey Kush.

In October 2018, the Company received a conditional use permit and business license from the City of Davis, California for cannabis manufacturing and state-wide distribution. A conditional use permit and business license for mobile delivery was issued by the City of Davis in November 2018. As of January 1, 2019, the Company's operations have been licensed by the State of California and the City of Davis, with plans to commence operations in 2019.

Please see the Issuer’s press releases dated February 27, 2019 and April 1, 2019 on the Issuer’s website for more information and the Issuer’s Form 9 posted on March 28, 2019 for further details.

8. Describe the acquisition of new customers or loss of customers.

Please refer to Question #1 for information on dispensary openings.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Oregon Secretary of State’s Office issued the trademark “CURALEAF” to Curaleaf, Inc., date of issue February 15, 2019. Registration Number: 50275

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Issuer has a total of 1,082 employees, which includes 69 new hires and 74 terminations in the month of March.

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Subordinate Voting Shares	643,285	Issued in connection with option exercises.	The proceeds of \$156,501.17 from payment of the option exercise prices will be used for general working capital purposes.

Subordinate Voting Shares	2,351,860	Issued as consideration for the acquisition of Eureka. Please see the Issuer's press release dated February 27, 2019 and April 1, 2019 on the Issuer's website for more information, the Issuer's Form 9 posted on March 28, 2019 and Section 7 of this report for further details.	No cash proceeds.
----------------------------------	------------------	--	--------------------------

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

N/A

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

N/A

[signature page follows]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 4, 2019.

Neil Davidson
Name of Director or Senior Officer

(signed) Neil Davidson
Signature
Chief Financial Officer
Official Capacity

Issuer Details Name of Issuer Curaleaf Holdings, Inc.	For Month Ended March 31, 2019	Date of Report YY/MM/D April 4 , 2019
Issuer Address 301 Edgewater Place #405		
City/Province/Postal Code Wakefield, MA 01880 USA	Issuer Fax No. ()	Issuer Telephone No. (781) 451-0150
Contact Name Christine Rigby	Contact Position SVP, Investor Relations	Contact Telephone No. (781) 451-0150
Contact Email Address info@curaleaf.com	Web Site Address www.curaleaf.com	